Labgenomics Co

Labgenomics Co FCF Margin

The Free Cash Flow Margin of Labgenomics Co (084650.KQ) as of Nov 14, 2026 is -36.52 %. In the previous year, Free Cash Flow Margin was -20.42 % — a change of 78.84% (lower).

FCF Margin

-36.52 %

YoY

78.84%

Last updated:

Free Cash Flow Margin of Labgenomics Co is 2025 -36.52 % . Free Cash Flow Margin of Labgenomics Co was 2024 -20.42 % . It decreases by 78.84% lower compared to the previous year.

The Labgenomics Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-5.15 KRW
Jan 1, 2019
7.92 KRW
Jan 1, 2020
38.23 KRW
Jan 1, 2021
25.52 KRW
Jan 1, 2022
21.78 KRW
Jan 1, 2023
-3.90 KRW
Jan 1, 2024
-20.42 KRW
Jan 1, 2025
-36.52 KRW
The Labgenomics Co FCF Margin history
YEARFCF MarginYoY
-36.52 %+78.84%
-20.42 %+423.17%
-3.90 %-117.92%
21.78 %-14.62%
25.52 %-33.25%
38.23 %+382.72%
7.92 %-253.64%
-5.15 %-76.15%
-21.61 %+239.13%
-6.37 %-33.16%
-9.54 %-213.80%
8.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Free Cash Flow Margin of Labgenomics Co is -36.52 % in 2025.

Free Cash Flow Margin of Labgenomics Co changed from -20.42 % to -36.52 %, representing a 78.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Labgenomics Co

All Key Metrics — Labgenomics Co